The 5 Minute Investor Podcast logo. (Source: Stockhouse)

Welcome to episode 71 of The 5-Minute Investor Podcast, where Stockhouse columnists Jonathon Brown and me, Trevor Abes, each deliver a 2.5-minute profile on a stock related to recent investment news. This week, with about 40 per cent of US citizens qualifying as obese, about 30 per cent in Canada, and more than 1 billion people affected across the world, weight-loss drugs have stepped into the pharmaceutical landscape as a convenient solution to this debilitating disease, presenting investors with several standout stocks worth considering for a potential investment.

This article is a journalistic opinion piece which has been written based on independent research. It is intended to inform investors and should not be taken as a recommendation or financial advice.

Here are Jon’s show notes for episode 71:

Here are Trevor’s show notes:

Here’s our most recent trio of episodes:

Thanks for listening!

The 5-Minute Investor Podcast is on SpotifyYouTubeiHeartRadio, Stockhouse or wherever finer podcasts are found.

Join the discussion: Find out what investors are saying about these weight-loss drug stocks on the Structure Therapeutics Inc. and Viking Therapeutics Inc. Bullboards and make sure to explore the rest of Stockhouse’s stock forums and message boards.

More From The Market Online

Jones Soda brings Fallout’s Nuka-Cola flavours to life

Jones Soda (CSE:JSDA) is launching a Fallout “Vault-Dweller Variety” Pack featuring Nuka-Cola Quartz, Cranberry, and Quantum.

@ the Bell: Market sentiment improves despite uncertainty

Canadian equities flatlined on Friday as investors assessed ongoing developments in the Middle East. Meanwhile, oil...

Silver rally sends Nicola Mining on BC treasure hunt

Nicola Mining kicks off an 800-metre drilling program at its 2,200-hectare Treasure Mountain silver project in British Columbia.

Michael Gentile keen to separate dirt from discovery with new investor forum

While every junior mining company thinks it's in line for a discovery, only a select few deserve high investor conviction.